Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate
Benzinga Newsdesk 7 months ago
EarningsEarnings MissesNews
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per share from the same period last year.